Rafael Holdings (RFL) Reports Q2 Loss of $0.08

Rafael Holdings (NYSE: RFL) reported Q2 EPS of ($0.08), versus ($0.04) reported last year. Revenue for the quarter came in at $1 million, versus $956 thousand reported last year.

"This quarter, we significantly increased our investment in Rafael Pharmaceuticals, purchasing a majority of the shares outstanding inclusive of interests held by minority holders in our subsidiaries.

"Rafael Pharma made excellent progress on its clinical trial program for difficult to treat cancers including the initiation of pivotal phase 3 trials of devimistat for patients with advanced metastatic pancreatic cancer and AML.

"LipoMedix Pharmaceuticals has initiated a phase 1b trial to identify the optimal dose, safety and efficacy of its lead compound Promitil® in combination with external beam radiotherapy in patients with advanced cancer requiring radiotherapy for inoperable primary tumors or metastatic disease.

"On the real estate side of our business, we continued our effort to monetize our properties including our 20-story commercial property and associated garage in Newark, New Jersey."

For earnings history and earnings-related data on Rafael Holdings (RFL) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Alight names three executives in leaves and broker partnerships
• Asia Broadband reports record $14.9M in H1 2026 gold and silver revenue